Hypertension.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D001018:Aortic Diseases / Q000150:complications; D001581:Benzothiadiazines; D001927:Brain Diseases / Q000150:complications; D002561:Cerebrovascular Disorders / Q000517:prevention & control; D003480:Cushing Syndrome / Q000150:complications; D003647:Debrisoquin / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000139:chemically induced; D004232:Diuretics; D006145:Guanethidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006333:Heart Failure / Q000517:prevention & control; D006801:Humans; D006929:Hyperaldosteronism / Q000150:complications; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000209:etiology; D006974:Hypertension, Malignant / Q000150:complications; D007008:Hypokalemia / Q000139:chemically induced; D007674:Kidney Diseases / Q000150:complications; D008750:Methyldopa / Q000009:adverse effects / Q000627:therapeutic use; D011654:Pulmonary Edema / Q000150:complications; D049993:Sodium Chloride Symporter Inhibitors / Q000009:adverse effects / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D001581:Benzothiadiazines; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D008750:Methyldopa; D003647:Debrisoquin; D006145:Guanethidine